✦ LIBER ✦

Total Cardiovascular Disease Burden: Comparing Intensive With Moderate Statin Therapy: Insights From the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial

✍ Scribed by Matti J. Tikkanen; Michael Szarek; Rana Fayyad; Ingar Holme; Nilo B. Cater; Ole Faergeman; John J.P. Kastelein; Anders G. Olsson; Mogens Lytken Larsen; Christina Lindahl; Terje R. Pedersen

Book ID: 119268634
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 455 KB
Volume: 54
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2009.08.035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Congestive heart failure is associated w

Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease: Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL)

✍ Ingar Holme; Timo E. Strandberg; Ole Faergeman; John J.P. Kastelein; Anders G. O 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Plasma Triglycerides and Cardiovascular

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

✍ Ole Faergeman; Ingar Holme; Rana Fayyad; Sonal Bhatia; Scott M. Grundy; John J.P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 471 KB

Impact of Smoking on Cardiovascular Even

Impact of Smoking on Cardiovascular Events in Patients With Coronary Disease Receiving Contemporary Medical Therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trials)

✍ Paul Frey; David D. Waters; David A. DeMicco; Andrei Breazna; Larry Samuels; And 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 475 KB

Comparison of Atorvastatin 80 mg/day Ver

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

✍ Terje R. Pedersen; Nilo B. Cater; Ole Faergeman; John J.P. Kastelein; Anders G. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 592 KB

Economic evaluation of high-dose (80&#xa

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

✍ Monika Wagner; Peter Lindgren; Elizabeth Merikle; Mireille Goetghebeur; Bengt Jö 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 856 KB

Cardiovascular outcomes and their relati

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

✍ I. Holme; R. Fayyad; O. Faergeman; J. J. P. Kastelein; A. G. Olsson; M. J. Tikka 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB